According to the registry, the combination of supportive therapy toprevent recurrent infections and the immunosuppressive treatment of immune dysregulationis often initiated early in life, with many patients undergoing multiple treatments.Rapamycin inhibits the biologically relevant downstream PI3K effector mTOR pathway, andit has been widely used with good efficacy in other PIDs, in particular, autoimmunelymphoproliferative syndrome (11, 12). Here, MTOR is linked to infection.